Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance

Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments Investor call today at 3 pm CET Dublin, Ireland--(Newsfile Corp. - July 23, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), a global leader in AI-driven healthcare ...